- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05068271
Multi-Domain Exercise and Memory in Adults Relative to ApoE Genotype: A fMRI Study
Effects of Multi-Domain Exercise Intervention on Memory Performance in Healthy Adults With and Without ApoE e4 Allele: A fMRI Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aging has been adversely associated with the deterioration of cognitive and brain functions. Most research on the effects of regular exercise on cognitive and brain functions has been focused on exercise programs with a single mode of exercise. Studies focusing on the effects of exercise programs with multi-domains on cognitive function and cortical functionality are sparse in late-middle-aged and older adults. In addition, while growing evidence has revealed the beneficial effects of regular exercise on cognitive function, scientific evidence regarding the effects of multi-domain exercise programs on cognitive function and brain function in late-middle-aged and older adults who are with or without the genetic risk for Alzheimer's disease (AD) is scarce. Lastly, the potential mediator role of the brain-derived neurotrophic factor (BDNF) in individuals is required to be explored.
In the current study, a single-blinded, double arm, 6-month randomized controlled trial has been utilized to assess the effects of a multi-domain exercise program containing multiple physical fitness components, meditation, and social interaction on memory, as well as cortical functionalities during the memory tasks in cognitively intact adults (i.e., 45-70 years). Specifically, the project aims to examine: (1) the causal links between a multi-domain exercise program composed of various physical fitness components, meditation, and social interaction against a control group on the memory performance in cognitively intact adults aged between 45 and 70 years with or without a genetic risk for AD, (2) the cortical functionality through functional images collected through a series of functional magnetic resonance images (fMRI), and (3) the potential influence of apolipoprotein epsilon-4 (ApoE e4) and BDNF on the effects of exercise.
One hundred eligible individuals will participate in the current study and will be randomly assigned into either the 6-month multi-domain exercise group (exercise group) or the online educational course group (control group).
All participants' physical fitness, cognitive function, and cortical functionalities via fMRI scanning will be assessed at the Baseline (Baseline-Assessments) and at the cessation of the 6-month intervention (Post-Assessments). The potential moderating role of ApoE genotypes and the mediation role of BDNF will be explored. Participation in this study will take approximately 7 months.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yu-Kai Chang, PhD
- Phone Number: +886277493220
- Email: yukaichangnew@gmail.com
Study Locations
-
-
-
Taipei, Taiwan, 106
- Not yet recruiting
- Yu-Kai Chang
-
Contact:
- Yu-Kai Chang, PhD
- Phone Number: +886277493220
- Email: yukaichangnew@gmail.com
-
Taipei City, Taiwan, 162
- Recruiting
- National Taiwan Normal University
-
Contact:
- Yu-Kai Chang
- Phone Number: +886277493220
- Email: yukaichangnew@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Normal or corrected-to-normal vision
- Able to speak and read Chinese
- Scores of Mini-Mental Status Examination >= 25
- Physical Activity Readiness Questionnaire score < 0
- Able to conduct the exercise with moderate intensity
- Meet the criteria to undergo magnetic resonance imaging
- Provide informed consent
Exclusion Criteria:
- Diagnosed or self-reported cognitive problems (e.g., mild cognitive impairment or dementia)
- Diagnosed or self-reported physical disease (e.g., untreated hypertension and chronic heart disease, stroke, brain tumor, musculoskeletal disorders, other exercise contradictions)
- Diagnosed or self-reported major psychiatric illness (e.g., major depression, schizophrenia)
- Diagnosed or self-reported neurodegenerative disease (e.g., Alzheimer's disease and other dementias, Parkinson's disease (PD) and PD-related disorders, Huntington's disease)
- History of alcohol or drug abuse
- History of chemotherapy
- Traveling consecutively for three weeks or more during the study
- Unwillingness to be randomized to one of the two groups
- Currently participating in another study trial
Exclusion Criteria for functional magnetic resonance images (fMRI):
Participants will be excluded if s/he has a contraindication to fMRI scanning, such as aneurysm clip, implanted neural stimulator, cochlear implant, any implanted device, cardiac pacemaker. To ensure volunteers are eligible for the current project, they will be asked to fill out a questionnaire to inform whether they have conditions (e.g. paralyzed hemidiaphragm) or present unnecessary risks (e.g., pregnancy) during the recruitment period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Multi-Domain Exercise Program
Time: 6 months, total of 150 min of exercise per week. Intervention: aerobic training, muscular fitness training, balance, flexibility, meditation, and social interaction. |
The multi-domain exercise consisted of the main exercise (e.g., aerobic exercise, resistance exercise, flexibility training, and coordinative exercise), social interaction, and meditation.
Participants are encouraged to engage in 150 min exercise per week consisting of one 90-min on-site session and multiple online sessions for 6 months.
|
|
Other: Control Group
Time: 6 months, total of 60 min of online educational course per week. Intervention: educational materials relating to the effects of exercise on cognitive function and aging-related cognitive decline. |
The "usual physical activity group," as the control group, is informed to maintain their lifestyles.
In addition, participants are invited to attend one 60-min online educational course per week.
The logs of physical activity behavior will be obtained from the participants once per month during the intervention period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in functional MRI indices
Time Frame: 60 min each at the Baseline-Assessment and at the Post-Assessment
|
Functional MRI assessments will be conducted at the baseline (Baseline-Assessment) and at the end of the 6-month intervention (Post-Assessment) to measure participants' brain functionalities.
Changes in functional MRI indices between the Baseline-Assessment and Post-Assessment will be assessed.
|
60 min each at the Baseline-Assessment and at the Post-Assessment
|
|
Changes in working memory performance: N-back working memory task
Time Frame: 30 min assessment time at the Baseline-Assessment and at the Post-Assessment
|
Working memory performance will be assessed using the computerized n-back working memory task at the baseline (Baseline-Assessment) and at the end of the 6-month intervention (Post-Assessment).
A total of 6 blocks with 108 trials (18 trials each block) will be utilized in the current study.
Changes in working memory performance between the Baseline-Assessment and Post-Assessment will be assessed.
|
30 min assessment time at the Baseline-Assessment and at the Post-Assessment
|
|
Changes in episodic memory performance: Relational and item-specific encoding and recognition test
Time Frame: 30 min each session at the Baseline-Assessment and at the Post-Assessment
|
Episodic memory performance will be assessed using the relational and item-specific encoding and recognition test at the baseline (Baseline-Assessment) and at the end of the 6-month intervention (Post-Assessment).
Changes in episodic memory performance between the Baseline-Assessment and Post-Assessment will be assessed.
|
30 min each session at the Baseline-Assessment and at the Post-Assessment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ApoE genotype
Time Frame: 5 min at the Baseline Assessment
|
Based on the genetic biomarkers (rs429358 and rs7412), participants' ApoE genotype will be determined.
|
5 min at the Baseline Assessment
|
|
Changes in blood neurotrophic marker: Brain-derived neurotrophic factor (BDNF)
Time Frame: 5 min each at the Baseline-Assessment and at the Post-Assessment
|
A 6 mL serum sample will be drawn from the antecubital vein at the baseline (Baseline-Assessment) and at the end of the 6-month intervention (Post-Assessment) to determine the concentration of BDNF.
Changes in BDNF levels between the Baseline-Assessment and Post-Assessment will be assessed.
|
5 min each at the Baseline-Assessment and at the Post-Assessment
|
|
Physical fitness measurements: Changes in aerobic fitness
Time Frame: 20 min each at the Baseline-Assessment and at the Post-Assessment
|
Participants' aerobic fitness will be estimated using the submaximal cycle ergometer test at the baseline (Baseline-Assessment) and at the end of the 6-month intervention (Post-Assessment).
Changes in aerobic fitness between the Baseline-Assessment and Post-Assessment will be assessed.
|
20 min each at the Baseline-Assessment and at the Post-Assessment
|
|
Physical fitness measurements: Changes in muscular fitness
Time Frame: 15 min each at the Baseline-Assessment and at the Post-Assessment
|
Muscular fitness will be assessed using either the push-up test/30sec or the chair stand test/30sec at the baseline (Baseline-Assessment) and the end of the 6-month intervention (Post-Assessment).
A higher number completed indicated a better level of muscular fitness.
Changes in muscular fitness between the Baseline-Assessment and Post-Assessment will be assessed.
|
15 min each at the Baseline-Assessment and at the Post-Assessment
|
|
Physical fitness measurements: Changes in flexibility
Time Frame: 15 min each at the Baseline-Assessment and at the Post-Assessment
|
Flexibility will be assessed using the sit-and-reach test at the baseline (Baseline-Assessment) and at the end of the 6-month intervention (Post-Assessment).
Further distance indicates better lower back and hip joint flexibility.
Changes in flexibility between the Baseline-Assessment and Post-Assessment will be assessed.
|
15 min each at the Baseline-Assessment and at the Post-Assessment
|
|
Physical fitness measurements: Changes in body composition
Time Frame: 15 min each at the Baseline-Assessment and at the Post-Assessment
|
The body composition (e.g., body water, body fat, skeletal muscle mass, body mass index, and percentage of body fat) will be assessed simultaneously using a body composition analyzer (ACCUNIQ BC380 Body Composition Analysis, SELVAS Healthcare Inc., Korea) at the baseline (Baseline-Assessment) and at the end of the 6-month intervention (Post-Assessment).
Changes in body composition between the Baseline-Assessment and Post-Assessment will be assessed.
|
15 min each at the Baseline-Assessment and at the Post-Assessment
|
|
Psychosocial measures: Changes in mindfulness
Time Frame: 5 min each at the Baseline-Assessment and at the Post-Assessment
|
Levels of mindfulness will be assessed using the 15-items (1-6 Likert scale) WHOQOL-OLD-Taiwan Chinese version of the Mindful Attention Awareness Scale questionnaire at the baseline (Baseline-Assessment) and at the end of the 6-month intervention (Post-Assessment).
Higher scores are associated with higher dispositional mindfulness.
Changes in mindfulness levels between the Baseline-Assessment and Post-Assessment will be assessed.
|
5 min each at the Baseline-Assessment and at the Post-Assessment
|
|
Psychosocial measures: Changes in sleep quality
Time Frame: 5 min each at the Baseline-Assessment and at the Post-Assessment
|
Sleep quality is assessed by the Pittsburgh Sleep Quality Index.
The questionnaire consists of 9 questions.
Lower scores are associated with better sleep quality.
Changes in sleep quality between the Baseline-Assessment and Post-Assessment will be assessed.
|
5 min each at the Baseline-Assessment and at the Post-Assessment
|
|
Psychosocial measures: Changes in depression
Time Frame: 5 min each at the Baseline-Assessment and at the Post-Assessment
|
Depression level is assessed by the Chinese version of the Geriatric Depression Scale (GDS-15).
The questionnaire consists of 15 'Yes/No' items.
The total scores between 5 and 9 indicate mild symptoms, and a score of 10 and above indicates moderate symptoms.
Changes in depression levels between the Baseline-Assessment and Post-Assessment will be assessed.
|
5 min each at the Baseline-Assessment and at the Post-Assessment
|
|
Psychosocial measures: Changes in health-related quality of life
Time Frame: 10 min each at the Baseline-Assessment and at the Post-Assessment
|
Health-related quality of life is assessed by the 24-items (1-5 Likert scale) WHOQOL-OLD-Taiwan.
The higher total scores indicate better quality of life.
Changes in health-related quality of life between the Baseline-Assessment and Post-Assessment will be assessed.
|
10 min each at the Baseline-Assessment and at the Post-Assessment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yu-Kai Chang, PhD, Department of Physical Education and Sport Sciences, National Taiwan Normal University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PACNL_WEBFIT: Memory & fMRI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aging
-
Tuba MadenCompletedAging | Aging Problems | Aging Disorder
-
Florida Institute for Human and Machine CognitionNot yet recruitingAging | Healthy Aging | Aging WellUnited States
-
University of CopenhagenRecruitingAging | Healthy Aging | Aging FrailtyDenmark
-
Radboud University Medical CenterTerminated
-
Northwestern UniversityPotocsnak Human Longevity LabRecruitingAging | Aging Well | Aging, Biological | Aging, HealthyUnited States
-
TruDiagnosticBlushield USANot yet recruitingAging | Aging Well
-
Arizona State UniversityActive, not recruiting
-
San Diego State UniversityCompleted
-
Lithuanian Sports UniversityCompletedAging | Healthy AgingLithuania
-
Centre Hospitalier Universitaire de NiceNot yet recruitingAging | Aging, HealthyFrance
Clinical Trials on Multi-Domain Exercise Program
-
Xuanwu Hospital, BeijingWuhan University; Beijing Friendship Hospital; First Affiliated Hospital Xi'an... and other collaboratorsRecruitingAmnestic Mild Cognitive ImpairmentChina
-
National Yang Ming UniversityCompleted
-
National Yang Ming Chiao Tung UniversityNational Health Research Institutes, TaiwanRecruitingAge-related Functional DeclineTaiwan
-
National Yang Ming UniversityNational Science and Technology CouncilCompletedAge-related Cognitive Decline | Age-related Physiology DeclineTaiwan
-
NeurocoreCompletedMild Cognitive ImpairmentUnited States
-
Geriatric Education and Research InstituteNeeuro Pte Ltd; Ministry of Health, Singapore; ProAge Pte Ltd; KKT Technology Pte...CompletedCognitive Decline | Cognitive Impairment, MildSingapore
-
New York University Abu DhabiNot yet recruitingMultiple Sclerosis | Multiple Sclerosis (MS) - Relapsing-remittingUnited Arab Emirates
-
Consorzio Futuro in RicercaUniversità degli Studi di Ferrara; Abbott Medical DevicesActive, not recruitingCoronary Artery Disease | Microvascular Angina | Microvascular Ischemia of MyocardiumItaly
-
University of Milano BicoccaCompletedAge-related Cognitive DeclineItaly
-
Fujian Provincial HospitalRecruitingCognitive DysfunctionChina